AZIENDA OSPEDALIERO UNIVERSITARIA MEYER
AZIENDA OSPEDALIERO UNIVERSITARIA XXXXX
Delibera del Direttore Generale n. 276 del 12-05-2023
Proposta n. 479 del 2023
Oggetto: ACCORDO DI RISERVATEZZA RECIPROCA DA SOTTOSCRIVERE CON GRACE SCIENCE, LLC PRELIMINARE A POSSIBILI FUTURI PROGETTI DI RICERCA– APPROVAZIONE SCHEMA DI ACCORDO
Dirigente: XXXXXXXX XXXXXXXX
Struttura Dirigente: RESP. XXXXX CHILDREN'S RESEARCH INSTITUTE
Delibera del Direttore Generale n. 276 firmata digitalmente il 12-05-2023
AZIENDA OSPEDALIERA UNIVERSITARIA XXXXX I.R.C.C.S.
Istituto di Ricovero e Cura a Carattere Scientifico Xxxxx Xxxxxxxxxx, 00 - 00000 XXXXXXX
C.F. P.Iva 02175680483
DELIBERAZIONE DEL DIRETTORE GENERALE
Oggetto | Studio clinico |
Contenuto | ACCORDO DI RISERVATEZZA RECIPROCA DA SOTTOSCRIVERE CON GRACE SCIENCE, LLC PRELIMINARE A POSSIBILI FUTURI PROGETTI DI RICERCA– APPROVAZIONE SCHEMA DI ACCORDO |
Area Tecnico Xxx.xx | AREA TECNICO AMMINISTRATIVA |
Coord. Area Tecnico Xxx.xx | XXXX XXXXX |
Struttura | XXXXX CHILDREN’S RESEARCH INSTITUTE |
Direttore della Xxxxxxxxx | XXXXXXXX XXXXXXXX |
Responsabile del procedimento | XXXXXXX XXXXXXXX |
Immediatamente Esecutiva | SI |
Spesa prevista | Conto Economico | Codice Conto | Anno Bilancio |
Estremi relativi ai principali documenti contenuti nel fascicolo | ||
Allegato | N° di pag. | Oggetto |
1 | 4 | Mutual Nondisclosure Agreement (Accordo di riservatezza reciproca) |
“documento firmato digitalmente”
IL DIRETTORE GENERALE
Visto il D. Lgs.vo n. 502 del 30.12.1992 recante “Riordino della disciplina in materia sanitaria” e s.m.i. e la
L. R. Toscana n. 40 del 24.02.2005 e s.m.i. di “Disciplina del Servizio Sanitario Regionale”;
Richiamata la L. R. Toscana n. 12 del 16.03.2023 “Disposizioni in materia di istituti di ricovero e cura a carattere scientifico pubblici. Modifiche alla l.r. 40/2005” con la quale si è proceduto alla disciplina degli istituti di ricovero e cura a carattere scientifico di diritto pubblico ed in particolare l’art. 13 con il quale sono state dettate le “Disposizioni transitorie per il passaggio da Azienda Ospedaliero Universitaria Xxxxx ad Azienda Ospedaliera Universitaria Xxxxx IRCCS…”;
Dato atto che:
- con deliberazione del Direttore Generale n. 54 del 01.02.2021 è stato approvato il nuovo Atto Aziendale dell’A.O.U. Xxxxx, ai sensi dell’art. 6 del Protocollo d’intesa del 22.04.2002 fra Regione Toscana e Università degli Studi di Firenze, Siena e Pisa, con decorrenza dal 01.02.2021;
- con deliberazione del Direttore Generale n. 55 del 01.02.2021 sono stati assunti i primi provvedimenti attuativi in relazione alla conferma/riassetto delle strutture complesse e semplici dotate di autonomia ed al conferimento dei relativi incarichi di direzione;
- con deliberazione del Direttore Generale n. 56 del 01.02.2021 sono state assunte determinazioni attuative del nuovo Atto aziendale in relazione alla conferma/riassetto delle strutture Dipartimentali e/o a valenza dipartimentale, delle Aree Funzionali Omogenee, dell’Area Servizi dell’Ospedale, dell’Area dei Diritti del Bambino, dell’Area Tecnico Amministrativa ed al conferimento di relativi incarichi di direzione;
- con successiva deliberazione del Direttore Generale n. 92 del 15.02.2021 si è provveduto ad assumere ulteriori disposizioni attuative relative all’organizzazione dell’A.O.U. Xxxxx in ordine alle Strutture semplici Intrasoc, Unità Professionali, Uffici e Incarichi professionali;
- con deliberazione del Direttore Generale n. 443 del 23.09.2022 l'A.O.U. Xxxxx ha disposto la presa d'atto del Decreto del Ministero della Salute del 02.08.2022, pubblicato nella Gazzetta Ufficiale n. 200 del 27.08.2022, con cui l’Azienda Ospedaliero Universitaria Xxxxx è stata riconosciuta Istituto di Ricovero e Cura a Carattere Scientifico (I.R.C.C.S.), per la disciplina di pediatria;
Richiamata la deliberazione n. 206 del 05.04.2023 con la quale si prende atto dell’attribuzione al Direttore Amministrativo, Dr. Xxxx Xxxxx, delle funzioni di Direttore Generale, ai sensi dell’art. 3, comma 6 del D. Lgs.vo n. 502/1992 e dell’art. 14 dell’Atto Aziendale;
Su proposta del Direttore Operativo del Xxxxx Children’s Research Institute, Dr.ssa Xxxxxxxx XxXxxxxx, la quale, con riferimento alla presente procedura, ne attesta la regolarità amministrativa e la legittimità dell’atto;
Ricordato che questa Azienda, tra le proprie finalità istituzionali, promuove la ricerca scientifica con lo scopo di raggiungere risultati di eccellenza nella cura in campo pediatrico e che taluni progetti di ricerca, prima del loro avvio, necessitano di una fase preliminare atta ad esplorarne la fattibilità presso le proprie strutture;
Considerato che Grace Science, LLC ha manifestato il proprio interesse in un settore della ricerca pediatrica che coinvolge il Xxxx. Xxxxx Xxxxxxxx e che è nelle intenzioni di questa Azienda esplorare la
possibilità di eventuali progetti di ricerca nel campo delle malattie rare concernenti le neuroscienze;
Stabilito che è, altresì, nell’interesse di questa Azienda garantire la valorizzazione della ricerca in pediatria e, pertanto, scambiare con la suddetta società, attraverso apposito Accordo di riservatezza reciproca, talune informazioni riservate necessarie per esaminare l’opportunità e la realizzabilità di futuri progetti di ricerca;
Dato atto che, per motivi inerenti alla tutela di informazioni sensibili concernenti i progetti di ricerca di Grace Science, LLC., quest’ultima ha proposto di omettere, ai fini della pubblicazione del presente atto, alcune parti sostanziali dell’Accordo sopra menzionato;
Visto l’art. 5-bis del D. Lgs. n. 33 del 14/03/2013 s.m.i., che disciplina l’esclusione e i limiti all’accesso civico;
Ritenuto di omettere ai fini della pubblicazione alcune parti del su citato Accordo individuate come omissis a tutela degli interessi di ricerca collegati alle informazioni confidenziali;
Vista la bozza di Accordo che, corredata dei necessari omissis, è unita quale allegato N. 1 al presente provvedimento a formarne parte integrante e sostanziale;
Verificato che dall’Accordo di cui sopra non derivano oneri economici a carico dell’AOU Xxxxx;
Ritenuto pertanto di stipulare l’Accordo reciproco di confidenzialità con Grace Science, LLC per la disciplina delle condizioni normative ed operative per la tutela delle informazioni confidenziali scambiate tra le parti dell’Accordo, nella versione integrale conservata agli atti;
Rilevata l’opportunità di dichiarare il presente atto immediatamente eseguibile per consentire che le informazioni confidenziali siano oggetto di reciproco scambio in tempi congrui con le esigenze di confronto, nel breve periodo, su progetti di ricerca tra le parti dell’Accordo;
Considerato che il Responsabile del Procedimento, individuato ai sensi della Legge n. 241/1990 nella persona del Dr. Xxxxxxx Xxxxxxxx, sottoscrivendo l’atto attesta che lo stesso, a seguito dell’istruttoria effettuata, nella forma e nella sostanza è legittimo;
Acquisito il parere del Dr.ssa Xxxxx Xxxx, Coordinatore dell’Area Tecnico Amministrativa, espresso mediante sottoscrizione del presente atto;
Vista la sottoscrizione del Direttore Sanitario e del Direttore Amministrativo, per quanto di competenza, ai sensi dell’art. 3 del Decreto Legislativo n. 229/99;
DELIBERA
Per quanto esposto in narrativa che espressamente si richiama,
1) Di approvare lo schema di Accordo di riservatezza reciproca da stipulare con Grace Science, LLC che, allegato N. 1 al presente atto, ne forma parte integrante e sostanziale.
2) Di dare atto che lo schema di Accordo di cui all’allegato N. 1 è pubblicato con omissis, ai sensi della normativa vigente e per le motivazioni espresse sopra, e che l’Accordo nella sua versione integrale è conservato agli atti.
3) Di dare atto che dall’Accordo di cui sopra non derivano oneri economici a carico dell’AOU Xxxxx IRCCS.
4) Di dichiarare il presente atto immediatamente eseguibile ai sensi dell’art. 42, comma 4 della
L.R. T. n. 40/2005 in considerazione della necessità di procedere in tempi brevi alla sottoscrizione del su citato Accordo e consentire così nell’immediato la discussione reciproca tra le parti su possibili futuri progetti di ricerca.
5) Di trasmettere il presente atto al Collegio Sindacale ai sensi dell’art. 42, comma 2, della L.R.T. n. 40/2005 contemporaneamente all’inoltro all’albo di pubblicità degli atti di questa A.O.U. Xxxxx I.R.C.C.S.
IL DIRETTORE GENERALE f.f. | |
(Dr. Xxxx Xxxxx) | |
IL DIRETTORE SANITARIO | IL DIRETTORE AMMINISTRATIVO |
(Dr.ssa Xxxxxxxxx Xxxxxxx) | (Dr. Xxxx Xxxxx) |
MUTUAL NONDISCLOSURE AGREEMENT
This Mutual Nondisclosure Agreement (“Agreement”), effective as of the last date of signature herein (“Effective Date”), is made and entered into by and between Grace Science, LLC, with an address of 0000 Xxxxx Xx. #0, Xxxxx Xxxx, XX 00000 (“GSL”), a Delaware Limited Liability Company and Xxxxx Children’s Hospital IRCCS, with registered office at Xxxxx Xxxxxxxx Xxxxxxxxxx 00, 00000 Xxxxxxx, Xxxxx (“Institution”), a public hospital of the Italian National Health Service. GSL and Institution may be referred to herein individually as a “Party” and collectively as “Parties.”
WHEREAS, each Party has developed or possesses certain Confidential Information (as hereinafter defined) that it desires to provide or make available to the other Party as set forth in this Agreement, solely for the following purpose (“Purpose”): (omissis).
WHEREAS, Xxxx. Xxxxx Xxxxxxxx, head of the Neuroscience Department, is the reference person for the Institution as regards the Purpose.
NOW, THEREFORE, in consideration of the foregoing and the mutual covenants herein contained, the Parties agree as follows:
1. Confidential Information.
1.1 “Confidential Information” means any and all proprietary or nonpublic information of a Party or its affiliates, including information that is written, electronic, oral or visual, that is directly or indirectly furnished, provided to or disclosed by or on behalf of a Party (“Disclosing Party”) to the other Party (“Receiving Party”) in connection with the Purpose, including each such Party’s affiliates and its and their members, principals, officers, directors, shareholders, trustees, employees, agents and advisors (“Representatives”). Confidential Information may include, without limitation, any and all information related to the business, financial condition, operations, results of operations, products or product candidates, technology, intellectual property, processes, customers, suppliers or partners of Disclosing Party. Confidential Information shall also include all notes, analyses, compilations, collections, forecasts or other documents or materials prepared by Receiving Party or its Representatives to the extent such documents or materials contain, reflect or are based on Confidential Information. Some terms and conditions of this Agreement and the Parties’ discussions regarding the Purpose will constitute Confidential Information. Confidential Information of GSL specifically includes, but is not limited to, information related to research and development on the impact of (omissis).
1.2 Each Party will use reasonable efforts to mark its Confidential Information as confidential, provided, however, any disclosure hereunder or information provided in connection with the Purpose that by its nature is in fact confidential and would be so judged under a reasonable standard, or that is disclosed, provided or obtained under circumstances reasonably indicating that such information is confidential or proprietary, will be considered Confidential Information regardless of whether marked or identified as confidential or proprietary.
1.3 Specific aspects or details of Confidential Information will not be deemed to be in the public domain or otherwise not subject to this Agreement merely because such aspects or details are embraced by more general information in the public domain or in Receiving Party’s possession. Any combination of individual elements of Confidential Information will be considered Confidential Information and will not be deemed to be in the public domain or otherwise not subject to this Agreement merely because one or more individual elements of such combination are in the public domain or already in Receiving Party’s possession; rather, such combination will only be considered in the public domain or in Receiving Party’s
Page 1 of 4
Grace Science, LLC – Confidential and Proprietary
Mutual NDA (Version: 12 May 2017)
possession if the individual elements of the combination are in a combined form and are in the public domain or in Receiving Party’s possession.
1.4 Confidential Information does not include any information that is:
1.4.1 lawfully and properly known by Receiving Party at the time of receipt and not through a prior disclosure by Disclosing Party, as documented by contemporaneous written evidence;
1.4.2 at the time of disclosure published, or otherwise thereafter becomes part of the public domain without breach of this Agreement by Receiving Party;
1.4.3 substantially disclosed to Receiving Party by a third party that is not obligated to maintain the confidentiality of such information; or
1.4.4 developed by Receiving Party independently of any Confidential Information, such development being documented by contemporaneous written evidence.
2. Term. Confidential Information may be disclosed pursuant to this Agreement beginning on the Effective Date and ending one (1) year thereafter unless extended by mutual written agreement of the Parties (“Term”).
3. Use and Disclosure. During the Term and for ten (10) years thereafter, Receiving Party will maintain Confidential Information in strict secrecy and confidence except as may be expressly authorized in this Agreement. Receiving Party will not, without Disclosing Party’s express written consent (a) disclose Confidential Information to any third party other than its Representatives as expressly provided herein, (b) use Confidential Information for any purpose other than the Purpose, (c) reverse engineer, copy, disassemble or otherwise attempt to reconstruct any physical embodiments, samples or prototypes of such Confidential Information or (d) incorporate, refer to or otherwise utilize all or any part of such Confidential Information to obtain any license or to apply for or to obtain any patent. Receiving Party agrees to use at least the same degree of care to prevent unauthorized disclosure of Confidential Information as it uses to protect its own information of like nature, and no less than a reasonable degree of care.
4. Disclosure to Representatives. Receiving Party may disclose Confidential Information only to Representatives who have a specific need to use such Confidential Information for the Purpose. All Representatives to whom Confidential Information has been disclosed will be advised of the existence and scope of this Agreement and will be subject to legally binding nondisclosure restrictions that are at least as restrictive as the terms of this Agreement. Each Party will be responsible for the acts and omissions of its respective Representatives under this Agreement as if such acts and omissions were performed (or not performed) by Receiving Party. If an act or omission of such Representative would constitute a breach of this Agreement if committed by Receiving Party, such act or omission will be deemed to constitute a breach of this Agreement by such Receiving Party.
5. Disclosure Required by Court Order or Governmental Regulation. If Receiving Party is required by law, court order or governmental authority to disclose Confidential Information, Receiving Party will promptly inform Disclosing Party in writing so that Disclosing Party may seek a protective order or other appropriate remedy. Receiving Party, to the extend legally permitted, will reasonably cooperate with Disclosing Party’s efforts to obtain any such order or other remedy. Receiving Party will disclose only that portion of the Confidential Information which Receiving Party determines is legally required to be disclosed and will exercise reasonable efforts to obtain assurance that confidential treatment will be accorded to such Confidential Information. Any Confidential Information so disclosed shall retain its confidential nature for all other purposes.
Page 2 of 4
Grace Science, LLC – Confidential and Proprietary
Mutual NDA (Version: 12 May 2017)
6. No Representation or Warranty. Disclosing Party makes no express or implied representation or warranty as to the accuracy, completeness or utility of its Confidential Information. RECEIVING PARTY ACKNOWLEDGES THAT THE CONFIDENTIAL INFORMATION OF DISCLOSING PARTY IS PROVIDED “AS IS,” WITHOUT ANY WARRANTY, EXPRESS OR IMPLIED.
7. Ownership; No License Implied; No Further Commitment. All Confidential Information of Disclosing Party (including all materials containing or incorporating such Confidential Information) provided pursuant to this Agreement will remain the sole and exclusive property of Disclosing Party. Disclosure of Confidential Information hereunder does not obligate either Party to enter into any future agreement relating to the Purpose, or to undertake any other obligation not otherwise set forth in a definitive written agreement. This Agreement will not be construed to grant to Receiving Party, by implication, estoppel or otherwise, any license or other rights with respect to the Confidential Information.
8. Return/Destruction. Upon written request of Disclosing Party at any time during the Term or within six (6) months thereafter, Receiving Party will, at its own cost and expense, promptly destroy or return to Disclosing Party all Confidential Information in possession of Receiving Party or its Representatives (in the medium originally provided), destroy all copies of the foregoing or any portion thereof, and destroy or redact all Confidential Information from all documents, samples, summaries, extracts, records or other materials that contain any Confidential Information, in whatever form or medium stored. Notwithstanding the foregoing, Receiving Party may retain one copy of the foregoing materials in a secure location solely for determining compliance with its obligations hereunder. Receiving Party will not be required to delete or destroy any electronic back-up tapes or files that are created and retained consistent with Receiving Party’s standard policy for automatic or routine archiving or back-up procedures.
9. Termination; Survival. Either Party may terminate this Agreement upon ten (10) days’ prior written notice to the other Party. Receiving Party’s obligations with respect to Confidential Information will survive termination of this Agreement. Any provision of this Agreement that by its nature is intended to survive such termination will so survive and continue to apply, including, without limitation, this Section 9.
10. Miscellaneous.
10.1 Assignment. Neither this Agreement nor the obligations hereunder may be assigned or otherwise transferred by a Party without written consent of the other Party.
10.2 Publicity. Each Party agrees that, except as required by applicable laws or government regulations or in connection with the potential assignment or other transfer of this Agreement, it will not, without the prior written consent of the other Party, publicize the existence of this Agreement or any of the terms hereof.
10.3 Applicable Law. This Agreement will be governed by and construed in accordance with the laws of the defendant party’s country, without reference to its rules of conflicts of laws. Any legal action involving this Agreement will be adjudicated in the courts of the defendant party.
10.4 Export Control Laws. Each Party agrees that it and its Representatives will comply with any applicable export control laws, rules and regulations relating to the export of technical information, materials or products in connection with any disclosure of Confidential Information.
Page 3 of 4
Grace Science, LLC – Confidential and Proprietary
Mutual NDA (Version: 12 May 2017)
10.5 Notices. Each notice required or permitted hereunder will be in writing and sufficient if delivered personally, sent by a nationally-recognized overnight courier or sent by registered or certified mail, postage prepaid, return receipt requested, to the Parties at the addresses indicated in the introductory paragraph of this Agreement, to the attention of the signatories below. Either Party may change its address by giving the other Party written notice, delivered in accordance with this Section.
10.6 Waivers and Amendments; Preservation of Remedies. This Agreement may be amended, or the terms and conditions may be waived, only by a written agreement signed by both Parties. No delay on the part of a Party in exercising any right hereunder will operate as a waiver, nor will any partial exercise of any right hereunder preclude any other exercise thereof. The rights and remedies herein are cumulative and are not exclusive of any rights or remedies that a Party may otherwise have at law or in equity.
10.7 Injunctive Relief. The Parties acknowledge that a breach of this Agreement may result in irreparable harm and damages in an amount difficult to ascertain and which cannot be adequately compensated by a monetary award. Accordingly, in addition to any of the relief to which a Party may be entitled under this Agreement, at law or in equity, such Party will be entitled to seek temporary and permanent injunctive relief from any breach or threatened breach without the requirement of such Party posting any bond or other security with the court in connection therewith.
10.8 Entire Agreement; Severability. This Agreement constitutes the entire understanding of the Parties with respect to the subject matter hereof and any express or implied agreements, either oral or written, are superseded by the terms of this Agreement. If any one or more provisions of this Agreement is held invalid, illegal or unenforceable in any respect by a court having competent jurisdiction, the validity, legality and enforceability of this Agreement and the remaining provisions contained herein will not in any way be affected or impaired thereby.
10.9 Counterparts. This Agreement may be executed in counterparts, each of which will be an original as against either Party whose signature appears thereon, but all of which taken together will constitute but one and the same instrument. An executed facsimile or electronic scanned copy of this Agreement will have the same force and effect as an original.
IN WITNESS WHEREOF, the Parties have executed this Agreement to be effective as of the Effective Date.
GRACE SCIENCE, LLC XXXXX CHILDREN’S HOSPITAL IRCCS
By: By:
Name: Name: Xxxx Xxxxx
Title: CEO Title: Acting CEO
Date: Date:
For acceptance and acknowledgement
Xxxx. Xxxxx Xxxxxxxx
Page 4 of 4
Grace Science, LLC – Confidential and Proprietary
Mutual NDA (Version: 12 May 2017)